StockNews.com Upgrades AC Immune (NASDAQ:ACIU) to “Buy”

StockNews.com upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a buy rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright decreased their target price on shares of AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, May 1st.

AC Immune Trading Up 2.6%

AC Immune stock opened at $1.57 on Tuesday. The company has a market cap of $157.64 million, a P/E ratio of -3.41 and a beta of 1.62. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.98. The company has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.48.

AC Immune (NASDAQ:ACIU) last released its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.99 million. On average, equities research analysts forecast that AC Immune will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ACIU. Geode Capital Management LLC grew its position in shares of AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after acquiring an additional 3,499 shares during the period. RPO LLC bought a new position in shares of AC Immune in the 4th quarter valued at about $51,000. Renaissance Technologies LLC grew its position in shares of AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock valued at $1,999,000 after acquiring an additional 94,191 shares during the period. Quinn Opportunity Partners LLC bought a new position in shares of AC Immune in the 4th quarter valued at about $27,000. Finally, Dimensional Fund Advisors LP grew its position in shares of AC Immune by 130.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after acquiring an additional 74,358 shares during the period. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.